New responsibilities led to US FDA missing PDUFA goals in FY 2008
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration’s performance under its prescription drug user fee programme was not up to the mark in fiscal year 2008, a report has revealed1,2. The agency failed to meet many of the goals it had promised to fulfil under the programme, under which it collects fees from pharmaceutical companies in return for meeting specific review targets.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.
EMA To Get The Ball Rolling On Making CTIS Global
The European Medicines Agency wants to further improve the visibility of data in the Clinical Trials Information System by establishing it as a World Health Organization primary registry.